Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Atai Life Sciences, UniQuest launch InnarisBio » 09:14
07/28/21
07/28
09:14
07/28/21
09:14
ATAI

Atai Life Sciences

$16.27 /

+0.065 (+0.40%)

atai Life Sciences and…

atai Life Sciences and UniQuest announced the launch of InnarisBio, to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. InnarisBio aims to commercialize the sol-gel intranasal drug delivery platform technology developed in the laboratory of UQ researcher Dr. Harendra Parekh at the School of Pharmacy in the Faculty of Health and Behavioural Sciences. The platform technology, which also includes a patent filing, was licensed to InnarisBio by UniQuest. Under the terms of the license, InnarisBio will receive exclusive rights in their desired fields. Florian Brand, CEO and co-founder of atai Life Sciences said, "This novel technology has the potential to be superior to other intranasal drug delivery methods available by improving absolute uptake and duration of uptake through muco-adhesion in the nose, reducing dose administered and dosing frequency. We plan to explore the potential use of this technology for a variety of psychedelic and non-psychedelic compounds across atai's platform." Under the terms of the license, InnarisBio will receive exclusive rights in their desired fields and UniQuest will receive equity in InnarisBio along with the potential to receive future development and commercial milestone payments and a royalty on product sales. InnarisBio will collaborate with UniQuest, UQ's Dr Parekh and his research team to formulate and develop bespoke sol-gel formulations for several psychedelic and non-psychedelic compounds nominated by InnarisBio.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$16.27 /

+0.065 (+0.40%)

07/14/21 Baader Helvea
Atai Life Sciences initiated with a Buy at Baader Helvea
07/13/21 Cowen
Atai Life Sciences initiated with an Outperform at Cowen
07/13/21 Canaccord
Atai Life Sciences initiated with a Buy at Canaccord
07/13/21 Cantor Fitzgerald
Atai Life Sciences initiated with an Overweight at Cantor Fitzgerald
  • 18
    Jun
ATAI Atai Life Sciences
$16.27 /

+0.065 (+0.40%)

ATAI Atai Life Sciences
$16.27 /

+0.065 (+0.40%)

Over a week ago
Initiation
Atai Life Sciences initiated with a Buy at Baader Helvea » 05:37
07/14/21
07/14
05:37
07/14/21
05:37
ATAI

Atai Life Sciences

$18.83 /

+0.04 (+0.21%)

Baader Helvea initiated…

Baader Helvea initiated coverage of Atai Life Sciences with a Buy rating and $21 price target.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.83 /

+0.04 (+0.21%)

07/13/21 Cowen
Atai Life Sciences initiated with an Outperform at Cowen
07/13/21 Canaccord
Atai Life Sciences initiated with a Buy at Canaccord
07/13/21 Cantor Fitzgerald
Atai Life Sciences initiated with an Overweight at Cantor Fitzgerald
07/13/21 Berenberg
Atai Life Sciences initiated with a Buy at Berenberg
  • 18
    Jun
ATAI Atai Life Sciences
$18.83 /

+0.04 (+0.21%)

ATAI Atai Life Sciences
$18.83 /

+0.04 (+0.21%)

Initiation
Atai Life Sciences initiated with an Outperform at Cowen » 08:55
07/13/21
07/13
08:55
07/13/21
08:55
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Cowen analyst Ritu Baral…

Cowen analyst Ritu Baral initiated coverage of Atai Life Sciences with an Outperform rating and no price target. The company's current pipeline consists of 10 therapeutics and six technologies focused on mental health disorders, Baral tells investors in a research note. The analyst believes Atai will create "much shareholder value" as its multiple candidates advance through the clinic and generate data in the next 12-18 months.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 Canaccord
Atai Life Sciences initiated with a Buy at Canaccord
07/13/21 Cantor Fitzgerald
Atai Life Sciences initiated with an Overweight at Cantor Fitzgerald
07/13/21 Berenberg
Atai Life Sciences initiated with a Buy at Berenberg
07/13/21 Citi
Atai Life Sciences initiated with a Buy at Citi
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with a Buy at Canaccord » 06:58
07/13/21
07/13
06:58
07/13/21
06:58
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Canaccord analyst Sumant…

Canaccord analyst Sumant Kulkarni initiated coverage of Atai Life Sciences with a Buy rating and $28 price target. The clinical-stage biopharma company has a decentralized model of development via acquisitions or creating new companies, which has given it a relatively large pipeline of 10 programs, half of which are psychedelics, Kulkarni noted. Though the stock is up about 25% since its IPO, Kulkarni sees "more upside to come" given the multi-billion dollar market opportunities for indications in which Atai expects to compete and what the analyst sees as "a steady stream of catalysts."

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 Cantor Fitzgerald
Atai Life Sciences initiated with an Overweight at Cantor Fitzgerald
07/13/21 Berenberg
Atai Life Sciences initiated with a Buy at Berenberg
07/13/21 Citi
Atai Life Sciences initiated with a Buy at Citi
07/13/21 RBC Capital
Atai Life Sciences initiated with a Sector Perform at RBC Capital
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with an Overweight at Cantor Fitzgerald » 06:57
07/13/21
07/13
06:57
07/13/21
06:57
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan initiated coverage of Atai Life Sciences with an Overweight rating and $45 price target. Atai is an emerging Neuro-Innovator that we believe could become a leader in developing drugs to facilitate a new paradigm for treating high unmet need mental health disorders, Duncan tells investors in a research note.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 Berenberg
Atai Life Sciences initiated with a Buy at Berenberg
07/13/21 Citi
Atai Life Sciences initiated with a Buy at Citi
07/13/21 RBC Capital
Atai Life Sciences initiated with a Sector Perform at RBC Capital
07/13/21 Credit Suisse
Atai Life Sciences initiated with an Outperform at Credit Suisse
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with a Buy at Berenberg » 06:37
07/13/21
07/13
06:37
07/13/21
06:37
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Berenberg initiated…

Berenberg initiated coverage of Atai Life Sciences with a Buy rating and $35 price target.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 Citi
Atai Life Sciences initiated with a Buy at Citi
07/13/21 RBC Capital
Atai Life Sciences initiated with a Sector Perform at RBC Capital
07/13/21 Credit Suisse
Atai Life Sciences initiated with an Outperform at Credit Suisse
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with a Buy at Citi » 06:28
07/13/21
07/13
06:28
07/13/21
06:28
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Citi analyst Neena…

Citi analyst Neena Bitritto-Garg initiated coverage of Atai Life Sciences with a Buy rating and $26 price target. The analyst cites the company's leadership position in the psychedelic medicine revolution for the Buy rating. Emerging data on the clinical benefit of psychedelics and increasing regulatory flexibility "has spurred a new wave of interest," Bitritto-Garg tells investors in a research note. The analyst expects continued regulatory de-risking, physician/patient enthusiasm, and an increasingly active public health conversation about mental health to make the stock appealing to both specialist and generalist investors.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 RBC Capital
Atai Life Sciences initiated with a Sector Perform at RBC Capital
07/13/21 Credit Suisse
Atai Life Sciences initiated with an Outperform at Credit Suisse
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with a Sector Perform at RBC Capital » 06:28
07/13/21
07/13
06:28
07/13/21
06:28
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams initiated coverage of Atai Life Sciences with a Sector Perform rating and $19 price target. Abrahams believes the company's valuation appropriately credits its broad assembly of promising assets and future leadership potential in an emerging neuropsych space, and expects in-line trade in the near-term as the company executes on its early clinical development and in-licensing strategies, until the programs mature further and more de-risking data emerge, the analyst tells investors in a research note.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/13/21 Credit Suisse
Atai Life Sciences initiated with an Outperform at Credit Suisse
07/08/21 Aegis
Atai Life Sciences initiated with a Buy at Aegis
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

Initiation
Atai Life Sciences initiated with an Outperform at Credit Suisse » 06:26
07/13/21
07/13
06:26
07/13/21
06:26
ATAI

Atai Life Sciences

$18.98 /

+0.33 (+1.77%)

Credit Suisse analyst…

Credit Suisse analyst Judah Frommer initiated coverage of Atai Life Sciences with an Outperform rating and $25 price target. The analyst believes Atai Life offers investors a diversified platform built around 10 development programs and six enabling technologies. These programs cover a wide range of mental health disorders including depression, substance use disorder, cognitive impairment, anxiety, and post-traumatic stress disorder, Frommer tells investors in a research note. The analyst thinks Atai is "attractively positioned" to capitalize on increased awareness around psychedelic drug development, with five of its programs leveraging psychedelic compounds.

ShowHide Related Items >><<
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

07/08/21 Aegis
Atai Life Sciences initiated with a Buy at Aegis
  • 18
    Jun
ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

ATAI Atai Life Sciences
$18.98 /

+0.33 (+1.77%)

On The Fly
Opening Day: Moving iMage moves up on market debut » 08:12
07/10/21
07/10
08:12
07/10/21
08:12
SNTG

Sentage

$34.25 /

-13.75 (-28.65%)

, RNAZ

Transcode Therapeutics

$5.26 /

-0.74 (-12.33%)

, AGRI

AgriFORCE Growing Systems

$5.60 /

+0.82 (+17.15%)

, MITQ

Moving iMage

$16.10 /

-7.28 (-31.14%)

, LDOC

LinkDoc Technology

/

+

, DIDI

DiDi

$12.04 /

+0.815 (+7.26%)

, BABA

Alibaba

$206.00 /

+6.04 (+3.02%)

, CYT

Cyteir Therapeutics

$18.70 /

+0.185 (+1.00%)

, FEMY

Femasys

$7.29 /

+0.02 (+0.28%)

, DNAY

Codex DNA

$17.23 /

-0.06 (-0.35%)

, AMAM

Ambrx Biopharma

$21.67 /

+0.68 (+3.24%)

, TRMR

Tremor International

$20.98 /

+2.06 (+10.89%)

, ATAI

Atai Life Sciences

$18.62 /

-1.06 (-5.39%)

, IPSC

Century Therapeutics

$27.35 /

+0.69 (+2.59%)

, VERV

Verve Therapeutics

$46.11 /

-0.09 (-0.19%)

, LYEL

Lyell Immunopharma

$15.87 /

+0.62 (+4.07%)

, ISPC

iSpecimen

$6.48 /

+0.13 (+2.05%)

, HOOD

Robinhood

/

+

, RGCB

Regencell Bioscience

/

+

, QNIU

Qiniu

/

+

, CMSL

Camposol

/

+

, SPRK

Spark Education

/

+

, BLND

Blend

/

+

, SCAN

Perspectum Group

/

+

, VTEX

VTEX

/

+

, GAMB

Gambling.com

/

+

, DUOL

Duolingo

/

+

, AUTH

Authentic Brands Group

$8.01 /

+ (+0.00%)

, RXST

RxSIGHT

/

+

Shares of Moving iMage…

ShowHide Related Items >><<
VERV Verve Therapeutics
$46.11 /

-0.09 (-0.19%)

HOOD Robinhood
/

+

DNAY Codex DNA
$17.23 /

-0.06 (-0.35%)

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

AMAM Ambrx Biopharma
$21.67 /

+0.68 (+3.24%)

SNTG Sentage
$34.25 /

-13.75 (-28.65%)

RNAZ Transcode Therapeutics
$5.26 /

-0.74 (-12.33%)

AGRI AgriFORCE Growing Systems
$5.60 /

+0.82 (+17.15%)

MITQ Moving iMage
$16.10 /

-7.28 (-31.14%)

LDOC LinkDoc Technology
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

07/08/21 Mizuho
Alibaba core EBITA estimates look 10% too high, says Mizuho
07/07/21 Needham
Alibaba may see deceleration in retail sales, says Needham
07/07/21 KeyBanc
Alibaba price target lowered to $270 from $275 at KeyBanc
07/06/21 HSBC
Alibaba price target lowered to $270 from $288 at HSBC
CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

FEMY Femasys
$7.29 /

+0.02 (+0.28%)

DNAY Codex DNA
$17.23 /

-0.06 (-0.35%)

AMAM Ambrx Biopharma
$21.67 /

+0.68 (+3.24%)

TRMR Tremor International
$20.98 /

+2.06 (+10.89%)

ATAI Atai Life Sciences
$18.62 /

-1.06 (-5.39%)

07/08/21 Aegis
Atai Life Sciences initiated with a Buy at Aegis
IPSC Century Therapeutics
$27.35 /

+0.69 (+2.59%)

VERV Verve Therapeutics
$46.11 /

-0.09 (-0.19%)

LYEL Lyell Immunopharma
$15.87 /

+0.62 (+4.07%)

06/29/21 Chardan
Iovance data show activity but 'not a home run,' says Chardan
ISPC iSpecimen
$6.48 /

+0.13 (+2.05%)

HOOD Robinhood
/

+

RGCB Regencell Bioscience
/

+

QNIU Qiniu
/

+

CMSL Camposol
/

+

SPRK Spark Education
/

+

BLND Blend
/

+

SCAN Perspectum Group
/

+

VTEX VTEX
/

+

GAMB Gambling.com
/

+

DUOL Duolingo
/

+

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

RXST RxSIGHT
/

+

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

  • 16
    Jul
  • 08
    Jul
  • 09
    Jul
  • 08
    Jul
  • 30
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 18
    Jun
  • 18
    Jun
  • 17
    Jun
  • 17
    Jun
LDOC LinkDoc Technology
/

+

HOOD Robinhood
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

AUTH Authentic Brands Group
$8.01 /

+ (+0.00%)

SNTG Sentage
$34.25 /

-13.75 (-28.65%)

RGCB Regencell Bioscience
/

+

LDOC LinkDoc Technology
/

+

HOOD Robinhood
/

+

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

CYT Cyteir Therapeutics
$18.70 /

+0.185 (+1.00%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

DIDI DiDi
$12.04 /

+0.815 (+7.26%)

BABA Alibaba
$206.00 /

+6.04 (+3.02%)

ATAI Atai Life Sciences
$18.62 /

-1.06 (-5.39%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.